Children < 5 years of age: 30 mg/kg/DAY IV divided q8h Children 5 to 11 years of age: 20-30 mg/kg/DOSE IV divided q8h-q12hChildren ≥12 years and adolescents: 20 mg/kg/DAY IV divided q12h; maximum 600 mg/DOSE
PNA <7 days and <1200 g: 20 mg/kg/DAY IV divided q12hPNA <7 days and ≥1200 g: 20-30 mg/kg/DAY IV divided q8-12hPNA ≥7 days and <1200 g: 20-30 mg/kg/DAY IV divided q8-12hPNA ≥7 days and ≥1200 g: 30 mg/kg/DAY IV divided q8h
No dosage adjustment recommended in hepatic insufficiency. Use in severe hepatic impairment has not been adequately evaluated.
No dosage adjustment necessary in renal insufficiency, however inactive metabolites may accumulate in renal insufficiency.
Targeted or empiric therapy for gram positive infections including skin and soft tissue, and pneumonia.
Covers MRSA and VRE
CBC at least once/week.
Visual testing for therapy >3mo or if symptoms develop on therapy.
Myelosuppression (usually with >2weeks therapy) - reversible
Peripheral/optic neuropathy with prolonged courses
Rash
Elevated liver enzymes
Lactic acidosis
SSRI and other serotonergics/MAOIs - increased risk of serotonin syndrome
Rifampin decreases linezolid levels.
Antimicrobial class: Oxazolidinone
Average serum half life:
Preterm neonates <1 week: 5.6 hours
Full-term neonates < 1 week : 3 hours
Full-term neonates ≥1 week to ≤ 28 days: 1.5 hours
Infants > 28 days to < 3 months: 1.8 hours
Infants and Children 3 months to 11 years: 2.9 hours
Adolescents: 4.1 hours
Adults: 4.9 hours
Route of Elimination:
Urine (~30% of total dose as parent drug, ~50 of total dose as inactive metabolites), two metabolites may accumulate in patients with severe renal impairment
Feces (9% of total dose as metabolites)
